Isolated diffusing capacity reduction in systemic sclerosis
- PMID: 1622414
- DOI: 10.1002/art.1780350709
Isolated diffusing capacity reduction in systemic sclerosis
Abstract
Objective: To determine the long-term outcome of patients with systemic sclerosis (SSc) and an isolated reduction in the diffusing capacity for carbon monoxide (DLCO) at the time of initial evaluation.
Methods: Patients with an isolated reduction in DLCO (i.e., normal forced vital capacity [FVC] and normal ratio of the forced expiratory volume in one second [FEV1] to the FVC) on initial evaluation were identified from among 815 patients with SSc who were carefully followed up throughout their illness. We requested that patients have repeat pulmonary function testing (PFT), and the outcomes of these tests, as well as cardiopulmonary and survival outcomes, were determined.
Results: An isolated reduction in DLCO, with a normal FVC was detected in 152 (19%) of the 815 patients. A subset of those with an isolated reduction in DLCO (11%) developed isolated pulmonary hypertension and had severely reduced survival rates. Pulmonary hypertension was strongly associated with an initial DLCO of less than 55% of predicted normal and a FVC (% predicted)/DLCO (% predicted) ratio of greater than 1.4. Among all patients in whom this ratio was greater than 1.4, 22% developed isolated pulmonary hypertension, compared with only 2% of those whose ratio was less than 1.4 (P less than 0.01). Of the 152 patients with isolated DLCO reduction, 73 (48%) underwent PFTs a mean of 5.4 years (range 2.0-13.2) after the initial PFT. Only 6 (8%) of these 73 patients ever had serious pulmonary disease: 5 had isolated pulmonary hypertension, and 1 had severe pulmonary fibrosis. Half of the patients with a low initial DLCO demonstrated a significant improvement (greater than 20%) at followup testing that could not be explained by the demographic, clinical, or laboratory findings at the first visit.
Conclusion: Isolated reduction in DLCO is a frequent abnormality in SSc. Overall, it is associated with a good prognosis for survival and for pulmonary morbidity. A small subset of patients (11%) who have a very low DLCO (less than 55% of predicted) have developed isolated pulmonary hypertension, all of whom had limited scleroderma.
Similar articles
-
Isolated DLco/VA reduction in systemic sclerosis patients: a new patient subset?Clin Rheumatol. 2018 Dec;37(12):3365-3371. doi: 10.1007/s10067-018-4342-5. Epub 2018 Oct 27. Clin Rheumatol. 2018. PMID: 30368639
-
Predictive value of isolated DLCO reduction in systemic sclerosis patients without cardio-pulmonary involvement at baseline.Reumatismo. 2015 Dec 23;67(4):149-55. doi: 10.4081/reumatismo.2015.837. Reumatismo. 2015. PMID: 27215180
-
Short-Term Pulmonary Function Trends Are Predictive of Mortality in Interstitial Lung Disease Associated With Systemic Sclerosis.Arthritis Rheumatol. 2017 Aug;69(8):1670-1678. doi: 10.1002/art.40130. Epub 2017 Jul 18. Arthritis Rheumatol. 2017. PMID: 28426895
-
Pulmonary function tests as outcomes for systemic sclerosis interstitial lung disease.Eur Respir Rev. 2018 May 15;27(148):170102. doi: 10.1183/16000617.0102-2017. Print 2018 Jun 30. Eur Respir Rev. 2018. PMID: 29769294 Free PMC article. Review.
-
Survival and prognostic factors in systemic sclerosis-associated pulmonary hypertension: a systematic review and meta-analysis.Arthritis Rheum. 2013 Sep;65(9):2412-23. doi: 10.1002/art.38029. Arthritis Rheum. 2013. PMID: 23740572 Review.
Cited by
-
Systemic sclerosis.Lancet. 2023 Jan 28;401(10373):304-318. doi: 10.1016/S0140-6736(22)01692-0. Epub 2022 Nov 25. Lancet. 2023. PMID: 36442487 Free PMC article. Review.
-
The promising role of lung ultrasound in systemic sclerosis.Clin Rheumatol. 2012 Nov;31(11):1537-41. doi: 10.1007/s10067-012-2030-4. Epub 2012 Jul 29. Clin Rheumatol. 2012. PMID: 22843171 Review.
-
Interstitial Lung Disease in Systemic Sclerosis: Focus on Early Detection and Intervention.Open Access Rheumatol. 2019 Dec 9;11:283-307. doi: 10.2147/OARRR.S226695. eCollection 2019. Open Access Rheumatol. 2019. PMID: 31849543 Free PMC article.
-
Prediction of pulmonary hypertension in idiopathic pulmonary fibrosis.Respir Med. 2007 Oct;101(10):2153-9. doi: 10.1016/j.rmed.2007.05.012. Epub 2007 Jul 2. Respir Med. 2007. PMID: 17604151 Free PMC article.
-
Evaluation of recently validated non- invasive formula using basic lung functions as new screening tool for pulmonary hypertension in idiopathic pulmonary fibrosis patients.Ann Thorac Med. 2009 Oct;4(4):187-96. doi: 10.4103/1817-1737.56013. Ann Thorac Med. 2009. PMID: 19881164 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical